Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

British Journal of Cancer

Volumn 114, Issue 5, 2016, Pages 505-509

  Tebbutt, Niall C ^a   Price, Timothy J ^b   Ferraro, Danielle A ^c   Wong, Nicole ^c   Veillard, Anne Sophie ^c   Hall, Merryn ^c   Sjoquist, Katrin M ^c   Pavlakis, Nick ^d   Strickland, Andrew ^e   Varma, Suresh C ^f   Cooray, Prasad ^g   Young, Rosemary ^h   Underhill, Craig ⁱ   Shannon, Jennifer A ^j   Ganju, Vinod ^k   Gebski, Val ^c  

^a AUSTIN HEALTH   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e MONASH MEDICAL CENTRE   (Australia)

^f TOWNSVILLE HOSPITAL   (Australia)

^g BOX HILL HOSPITAL   (Australia)

^h ROYAL HOBART HOSPITAL   (Australia)

ⁱ Border Medical Oncology Australia   (Australia)

^j Nepean Cancer Care Centre   (Australia)

^k FRANKSTON HOSPITAL   (Australia)

more..

Author keywords

Chemotherapy; Docetaxel; Oesophago gastric cancer; Panitumumab; Randomised study

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; PANITUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ACNE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPHAGIA; EPIPHORA; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAIR LOSS; HAND FOOT SYNDROME; HEARING IMPAIRMENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; TREATMENT RESPONSE; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FATIGUE; GASTROESOPHAGEAL JUNCTION; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; SECONDARY; STOMACH NEOPLASMS; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANOREXIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DIARRHEA; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; INFECTION; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NAUSEA; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME; VOMITING;

EID: 84959369848     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.440     Document Type: Article

References (18)

1. Al-Batran S-E, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E. Arbeitsgemeinschaft Internistische Onkologie. (2008). Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internisticsche Onkologie. J Clin Oncol. 26(9): 1435-1442.
2. Cook N, Marshall A, Blazeby J, Bridgewater J, Wadsley J, Coxon F, Mansoor W, Madhusudan S, Falk S, Middleton G, Swinson D, Chau I, Thompson J, Cunningham D, Kareclas P, Dunn J, Ford H. (2013). Cougar-01: a randomised phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. J Clin Oncol. 31(15-suppl): abstract 4023.
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358: 36-46.
4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R. (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 8: 163-168.
5. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. (2007). Cetuximab for the treatment of colorectal cancer. N Engl J Med. 357(20): 2040-2048.
6. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Höfler H, Sarbia M. (2006). Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in esophageal adenocarcinoma: a tissue microarray study. J Clin Pathol. 59: 631-634.
7. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO. (2011). Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 25(6): 1517-1524.
8. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. (2008). Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 15(1): 69-79.
9. Lordick F, Kang Y-K, Chung H-C, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M. Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. (2013). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 14(6): 490-499.
10. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 72(1): 37-41.
11. Muro K, Hamaguchi T, Ohtsu A. (2004). A phase II study of single-Agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004 16(6): 955-959.
12. Navarini D, Gurski RR, Madalosso CA, Aita L, Meurer L, Fornari F. (2012). Epidermal growth factor receptor in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy. Gastroenterol Res Pract. 2012: 941954.
13. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J. Australasian Gastro-Intestinal Trials Group. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 102(3): 475-481.
14. Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ. Australasian Gastro-Intestinal Trials Group (AGITG. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. Br J Cancer. 108: 771.
15. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. V325 Study Group. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 24(31): 4991-4997.
16. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 25(13): 1658-1664.
17. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. (2013). Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 14: 481-489.
18. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. (2006). Chemotherapy in advanced gastric cancer: a systematic review and meta-Analysis based on aggregate data. J Clin Oncol. 24(18): 2903-2909.